Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.



The grant will be used to develop an improved animal model for acute liver failure in pigs that resembles much more the clinical situation of acute liver failure in humans than currently available models. This new model will allow to analyzing and evaluating the safety and efficacy of the Hepa Wash® treatment on the function of vital organs during acute liver failure, results that will be very important for the further development and optimization of the Hepa Wash® device. In addition, these data will also be very helpful to gain a better insight into the underlying pathology of acute liver failure, a disease that is still only partially understood.

Bernhard Kreymann, CEO and founder of Hepa Wash, comments “We are very proud that our efforts in the development of a new and innovative liver therapy will be supported by the Bayerische Forschungsstiftung. This grant will help us significantly in our attempt to achieve a breakthrough in the current therapeutic practice for patients with severe liver failure. In addition, it demonstrates the commitment of the BFS to support innovative applied research projects thereby not only contributing to the development of small, high-potential companies but also further strengthening medical technology as one of the future key technologies for the benefit of patients as well as Bavaria as a business location. We are also very delighted to have the opportunity to work together on this project with several prestigious partners, especially Prof. Dr. med. Roland M. Schmid from the University Hospital Rechts der Isar, PD Dr. Bernhard Michalke from the GSF, Neuherberg, and Prof. Dr. Dr. med. h.c. Peter Rademacher from the Clinic for Anaesthesiology in Ulm.”

End-stage liver disease
Liver failure is one of the dominant causes of death worldwide. In the eight economically leading countries of the world alone, more than 100,000 patients die from liver diseases each year. Despite numerous efforts, at present, the only reliable curative therapy is liver transplantation. However, transplantation is and will be in the future only a therapy for a minority of patients. Thus, there is an urgent need for a liver assist device to reduce the very high mortality and morbidity of liver patients.

About Hepa Wash
Hepa Wash GmbH, a Munich-based medical device company, is dedicated to the development and commercialization of its innovative liver assist technology that is expected to be several times more effective than currently available treatments and to create a breakthrough in the treatment of liver patients that will change current medical practice.

Publisher Contact Information:

Hepa Wash GmbH

Company profile of Hepa Wash GmbH
Past press releases of Hepa Wash GmbH.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.